Sunday, November 8, 2009

Multiple Sclerosis Home>
Multiple Sclerosis News>
10th Tysabri-related brain inflammation case reported

Font size
- A
- A
- A
Email This

Bookmark

Save

Receive a FREE Osteoarthritis of the knee pamphlet. Start here.

10th Tysabri-related brain inflammation case reported

(Business Week) UPDATED 2009-06-29

Drugmaker Biogen Idec Inc. is reporting a tenth case of a potentially lethal form of brain inflammation in a user of its drug Tysabri. Company officials confirmed the presence of progressive multifocal leukoencephalopathy (PML) in a patient who had been using Tysabri for 30 months. Tysabri was pulled from the market in 2005 because of concerns about PML, and sales resumed in July 2006 with restrictions and a monitoring program. The drug is approved to treat both multiple sclerosis (MS) and Crohn's disease, but all 10 cases of PML have been in patients with MS. Read full story >

See all Multiple Sclerosis News

Related: Tysabri

Font size
- A
- A
- A
Email This
Bookmark

Was this helpful? Yes
Save

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on MultipleSclerosisCentral.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2009. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.